PCM
CANF

Prelude Capital Management’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Prelude Capital Management’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Hold
0
– -$2K – 1382
2017
Q3 		– Hold
0
– – – 1553
2017
Q2 		– Hold
0
– – – 1548
2016
Q3 		– Sell
-1
Closed -$7K – 1604
2016
Q2 		$7K Buy
+1
New +$8.46K ﹤0.01% 1424

Other funds holding CANF

TAM
Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WWMSC
Wagner Wealth Management (South Carolina) Greenville, South Carolina $541M AUM 12.14% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Prelude Capital Management's CANF Position: Q4 2017 in Review

Prelude Capital Management held its Can-Fite BioPharma American Depositary Shares (CANF) position steady in Q4 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

Prelude Capital Management first reported a position in CANF in Q2 2016 and has held it in 1 quarter since. The position peaked at $7K in Q2 2016. 8 funds tracked by Wall St. Rank hold CANF as of Q4 2017.

  • Prelude Capital Management held 0 shares of Can-Fite BioPharma American Depositary Shares worth $0 as of Q4 2017.
  • Prelude Capital Management left its Can-Fite BioPharma American Depositary Shares share count unchanged in Q4 2017.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Prelude Capital Management's portfolio in Q4 2017, its #1382 holding.
  • Prelude Capital Management first reported a position in Can-Fite BioPharma American Depositary Shares in Q2 2016 and has held it in 1 quarter since.
  • Prelude Capital Management's Can-Fite BioPharma American Depositary Shares position peaked at $7K in Q2 2016.
  • 8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.